The present finding is in line with the notion that HD can be considered as a novel, safe, and promising therapeutic target in HF.25, 26 In this regard, the American Heart Association recommends to test for GHD in patients with dilated cardiomyopathy who have signs and symptoms of GHD,27 and the eventual presence of the primary deficit in GH levels should be appropriately treated (namely, GH cardiomyopathy).27 Most recent European guidelines considered T therapy as a possible treatment for cachexia and sarcopenia in combination with nutritional supplements.15 Here, GH1 is linked to dilated cardiomyopathy.